This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, PK, and immunogenicity of multiple subcutaneous doses of TRIV-509 in participants 18 to
75 years of age with moderate to severe AD.
Volunteers needed for up to a 57-week-long clinical trial with up to 14 office visits for an investigational product. Stipend up to $1980 if eligible.
To Qualify, you must meet the following INCLUSION CRITERIA:
1.) 18-75 years of age.
2.) Have moderate to severe eczema (atopic dermatitis).
3.) Must weigh more than 88.2 lbs.
To Qualify, you must NOT meet the following EXCLUSION CRITERIA:
1.) History of cancer or lymphoproliferative disease within the last 5 years.
2.) Test positive for HIV.
3.) Be pregnant or plan on becoming pregnant.
ClinicalTrials.gov ID NCT07167758

We love our patients, so feel free to visit during normal business hours.
510 S Cowley Spokane, WA 99202
Mon | 09:00 am – 05:00 pm | |
Tue | 09:00 am – 05:00 pm | |
Wed | 09:00 am – 05:00 pm | |
Thu | 09:00 am – 05:00 pm | |
Fri | 09:00 am – 05:00 pm | |
Sat | Closed | |
Sun | Closed |
Copyright © 2026 Principle Research Solutions,llc - All Rights Reserved.
Your One-Stop Research SOLUTION
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.